WO1995015177A3 - Improved efficacy of alpha-helical cytokines - Google Patents

Improved efficacy of alpha-helical cytokines Download PDF

Info

Publication number
WO1995015177A3
WO1995015177A3 PCT/US1994/013836 US9413836W WO9515177A3 WO 1995015177 A3 WO1995015177 A3 WO 1995015177A3 US 9413836 W US9413836 W US 9413836W WO 9515177 A3 WO9515177 A3 WO 9515177A3
Authority
WO
WIPO (PCT)
Prior art keywords
cytokine
cell
helical
cells
alpha
Prior art date
Application number
PCT/US1994/013836
Other languages
French (fr)
Other versions
WO1995015177A2 (en
Inventor
Michael E Greenberg
Azad Bonni
David A Frank
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Priority to AU12992/95A priority Critical patent/AU1299295A/en
Publication of WO1995015177A2 publication Critical patent/WO1995015177A2/en
Publication of WO1995015177A3 publication Critical patent/WO1995015177A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma

Abstract

The present invention provides methods and compositions for potentiating the efficacy of an α-helical cytokine in regulating development and/or maintenance of a cytokine-responsive cell, espeically neuronal cells. The subject method stems from the finding that contacting a cell with an agent which induces upregulation of the intracellular concentration of a 91 kd protein can produce enhanced responsiveness of the cell to treatment with an α-helical cytokine. The subject method comprises administering a p91-inducing agent in an amount sufficient to potentiate the trophic activity of an α-helical cytokine, such as CNTF or LIF, on a population of cells, and thereby enhance the ability of the cytokine to regulate differentiation of the treated cells, and/or prevent cell death.
PCT/US1994/013836 1993-12-02 1994-12-02 Improved efficacy of alpha-helical cytokines WO1995015177A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12992/95A AU1299295A (en) 1993-12-02 1994-12-02 Improved efficacy of alpha-helical cytokines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16167293A 1993-12-02 1993-12-02
US08/161,672 1993-12-02

Publications (2)

Publication Number Publication Date
WO1995015177A2 WO1995015177A2 (en) 1995-06-08
WO1995015177A3 true WO1995015177A3 (en) 1995-09-14

Family

ID=22582224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/013836 WO1995015177A2 (en) 1993-12-02 1994-12-02 Improved efficacy of alpha-helical cytokines

Country Status (2)

Country Link
AU (1) AU1299295A (en)
WO (1) WO1995015177A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604858A1 (en) * 1996-02-10 1997-08-14 Boehringer Ingelheim Int Interferon-gamma for treating or preventing amyloid precursor protein related diseases
KR101712556B1 (en) * 2014-08-27 2017-03-08 서울대학교산학협력단 Method for differentiation into retinal ganglion cells from stem cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005805A1 (en) * 1990-10-01 1992-04-16 Research Development Foundation Synergism of tnf and il-4
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
WO1993021229A1 (en) * 1992-04-15 1993-10-28 Amgen Inc. Methods and compositions for the treatment of diseases with interferon while reducing side effects

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005805A1 (en) * 1990-10-01 1992-04-16 Research Development Foundation Synergism of tnf and il-4
WO1992006707A1 (en) * 1990-10-17 1992-04-30 Amgen Inc. Methods and compositions for the treatment of cell proliferation disorders
WO1993021229A1 (en) * 1992-04-15 1993-10-28 Amgen Inc. Methods and compositions for the treatment of diseases with interferon while reducing side effects

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE WIT H. ET AL: "Interferon-gamma enhances the LPS-induced G-CSF gene expression in human adherent monocytes, which is regulated at transcriptional and posttranscriptional levels", EXP. HEMATOL., 1993, 21/6 (785-790), USA *
LARNER A C ET AL: "TYROSINE PHOSPHORYLATION OF DNA BINDING PROTEINS BY MULTIPLE CYTOKINES", SCIENCE (WASH D C), 261 (5129). 1993. 1730-1733. *
SILVENNONOINEN O ET AL: "RAS-INDEPENDENT GROWTH FACTOR SIGNALING BY TRANSCRIPTION FACTOR TYROSINE PHOSPHORYLATION", SCIENCE (WASH D C), 261 (5129). 1993. 1736-1739. *

Also Published As

Publication number Publication date
WO1995015177A2 (en) 1995-06-08
AU1299295A (en) 1995-06-19

Similar Documents

Publication Publication Date Title
DK0597033T3 (en) IGF-1 to improve the neural state
DE69731540D1 (en) TREATMENT OF DIARRHOE
UA74325C2 (en) HETEROCYCLIC INHIBITORS р38, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND A METHOD FOR TREATMENT WITH THEIR USE
ATE270111T1 (en) COMPOSITION AND METHOD FOR REDUCING THE TOXICITY OF BIOLOGICALLY ACTIVE FACTORS
ATE139447T1 (en) AGENT FOR ENHANCING THE EFFECT OF ANTITUMORAL AGENTS AND FOR COMBAT RESISTANCE TO MULTIPLE DRUGS
ES2130574T3 (en) CYTOKINE RESTRICTION AGENTS.
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
MX9206577A (en) PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF TUMOR CELLS
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
NO931141L (en) TNF mutein
CA2122058A1 (en) Tgf-beta to improve neural outcome
DK0572688T3 (en) Peptides, with organ-protective activity, method for their preparation and their use in therapy
MX9706689A (en) Treatment of cytokine growth factor caused disorders.
DK393188A (en) PHARMACEUTICAL PREPARATION FOR INTRANASAL ADMINISTRATION
WO1995015177A3 (en) Improved efficacy of alpha-helical cytokines
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
GR3029319T3 (en) Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity
EP0642333A4 (en) Method and composition for the treatment of disorders involving immunological dysfunction.
DE60036638D1 (en) USE OF COLOSTRININ, THEIR PEPTIDE COMPONENTS AND THEIR ANALOGUE FOR PROMOTING NEURONAL CELL DIFFERENTIATION
PL313257A1 (en) Novel tripeptides useful in treating immune system and central nervous system
UA27055C2 (en) Medicinal preparation of immunoreplacement activity the basis of cellular suspension and method for treatment of acquired immune deficiency syndrome by the use of this preparation
EP0495998A4 (en)
DK0658117T3 (en) Treatment of tumors with neurotrophic factors and cell proliferation inhibitors
CA2297984A1 (en) Ratite extracts as therapeutic agents
RO94381B1 (en) Medicinal product for supporting the medium and long time effort

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA